2. Shresth Pharma Nexus(SPN) is a business
consulting company active within the field
of Pharmaceuticals and Health Care. It
specialises in providing a Global network to
its customers, allowing them to choose from
the best in the market. The idea is to bring
the market to the customer, providing them
solutions and making business an easy task.
We work with organizations in the arena of
strategic management, which requires a
distinctive approach from operational
management.
Client Confidential
3. Our key role is to build the road to your
prosperity:
We Lay Foundation for Future Growth
Client Confidential
4. Range of Services
Business plan review
Organizational review
Market Assessment
Business Consultancy
& Intelligence
For Merger, Acquisition
& Disposal
Registration of API/FF
Shresth Pharma Nexus Strategic tie-ups
With DCGI, India
Enterprise Risk Project Evaluation
Management
CRAMs & Analytical
Services
Client Confidential
5. What We Offer
Finished
API
Formulation
Manufacturer
Manufacturer
Sourcing Intermediates
Sourcing of API
from India/China
Sales & Marketing In & Out Licensing
Custom Synthesis CRAMs
Generic NDDS, Formulation
Technology
dossier
Whole chain of analytical
Turn Key Projects
services.
Client Confidential
6. Our Philosophy
We comprehend our customers’ needs
accurately and provide them with best
business alternatives, as we believe that
business should always be customer driven.
However, we offer more than mere business.
We help you make relations and partnership
that lead towards triumph. We give
importance to confidentiality and
transparency in our business. And that is our
motive to deliver, with honesty and trust.
Our key role is to build the road to your
prosperity.
“We Lay Foundation for
Future Growth”
Client Confidential
8. Projected Growth of
Indian Pharmaceutical Market
Currently Forecasted Growth for 2020
• Total Worth $19billion • Increase to $50billion
– Domestic Market: $11bn – Domestic Market: $30bn
– Exports: $8bn – Exports: $20bn
• Ranked 14th in World • Will be one of top 10 markets
Source: PwC, Global pharma looks to India: Prospects for growth
Client Confidential
9. India is expected to be the 7th largest
market by 2020
Top Pharma Markets 2015* & 2020 (US$ bn)
Source: BCG, Goldman Sachs,
McKinsey Reports
However, among all Top 10 global markets of 2015 India shows the highest growth rate
among all countries analysed by McKinsey
Client Confidential
11. Assessing the Capabilities of
API Manufacturers
Leading companies with business experience, regulatory, quality, non-infringing
processes, and track record of supplying regulated markets Established
Meet regulatory, quality, & other criteria for limited number of
Less
molecules. May be moving from older to new molecules, may supply
intermediates to Established companies.
Established
Companies usually make older molecules, may supply
Potential
intermediates to Established companies, often working to
upgrade & forge links with dose firms in major markets Future
Companies serving their local markets. Lack
quality, regulatory, experience to supply major Local
markets
Able to satisfy local markets Global markets
Unregulated cGMP, FDA Inspected
Older molecules New molecules
Client Confidential
16. Indian API Manufacturer Ratings
2004 to 2010
100 92
90
80
Number of Corporate Groups
70
56
60
50
40
40 2004
24 2010
30
18
17
20
10
0
Established Less Established Potential Future
Corporate API Rating Assessed by Thomson Reuters
Source: Newport Premium™ Client Confidential
17. Capabilities of
Indian API Manufacturers
24 corporate groups, 34 API sites
Established
e.g., Cipla, Dr. Reddy’s
40 corporate groups, 47 API sites Less
e.g., MSN, Hetero Established
92 corporate groups, 91 API sites Potential
e.g., Emcure, Sai Advantium Future
480 corporate groups, 492 API sites
e.g., SMILAX Laboratories Local
Able to satisfy local markets Global markets
Unregulated cGMP, FDA Inspected
Older molecules New molecules
Client Confidential
18. Comparing the Ability of Indian and
Chinese Manufacturers to Supply
Regulated Markets
160 150
140
Number of Corporate Groups
120
92
100
80
India
60 China
40
34
40
24
12
20
0
Established Less Established Potential Future
Corporate Rating Assessed by Thomson Reuters
Source: Newport Premium™
Client Confidential
19. DMFs & COS by India & China
Client Confidential
20. Year wise US DMFs Submitted by India & China
2009 94
350
2008 119
382
2007 122
331
2006 64
283
2005 52
257
33
2004 184 China
35
2003 114 India
2002 25
63
2001 5
44
2000 15
31
1999 5
23
0 100 200 300 400
Number of US DMFs
Source: Newport Premium™
Client Confidential
21. COSs Granted 2000 to 2009 to
India, Italy, China & ROW (includes US)
2000 2009
India
24%
China
10%
ROW
54%
Italy
12%
459 COS 2722 COS
Source: Newport Premium™ Client Confidential
22. US ANDAs Held by Indian
Companies
180
160
17 29
140
Number of US ANDAs
21
120
100
80 Tentative
19 147
139
Approved
60 117
10
11
40
63
20 42 38
14 12 18
0 10
0 2
Year
Source: Newport Premium™
Client Confidential
23. Increase in Indian Holders
of US ANDAs
180 30
168
164
160
Number US ANDAs by Indian Companies
Number of India Based ANDA Holders
25
138
140
120 20
100
82 15
80
60 52 10
49
40
5
18
20 14 12
10
2
0 0
Source: Newport Premium™
Client Confidential
24. Top Ten Paragraph IV Challengers
by Volume
160 149
140
Number of PIV Challenges
120
100
80 75 72
57 55
60
42 39
40 32 30 27
20
0
Source: Newport Premium™
Client Confidential
26. Acquisitions by Foreign Companies
of Indian Targets
80 76
72
70 68
65
Number of Acquisitions
60 56
50 47
45
43 42
40 38
30
20
10
0
Year
Source: Newport Premium Deals Module™
Client Confidential
27. Significant Foreign Acquisitions of
Indian Companies
Mylan’s acquisition of Matrix (2006)
Daiichi’s acquisition of Ranbaxy (2008)
Hospira’s acquisition of Orchid’s injectable business
(2009)
Abbott’s acquisition of Piramal’s Healthcare Solutions
Business (2010)
Source: Company websites
Client Confidential
28. Indian Acquisitions of Foreign Companies
Sun acquired Caraco (2004) & ICN Hungary (2005)
Dr Reddys acquired Betapharm Arzneimittel GmbH (2006)
Strides acquired Diaspa SpA (2007)
Lupin acquired Kyowa Pharmaceutical Industry co Ltd (2007)
Dishman acquired Solvay Pharmaceuticals BV - Fine Chemical & Vitamin Business
(2007)
Sun acquired Chattem’s controlled substance facility (2008)
Piramal acquired Minrad International (2008)
Source: Company websites
Client Confidential
29. Biotech Capabilities Among Top Indians
Company Recombinant Monoclonal Vaccines Launches
Proteins Antibodies
Biocon FP FP EPO, MAb
Shantha FP UD INF, GCSF
Intas FP UD GCSF, INF, EPO
Panacea FP Vaccines
Lupin FP
Zydus FP FP
Torrent FP Insulin
Wockhardt FP UD Insulin, INF, CGSF,
EPO
Glenmark UD FP Novel only
Bharat UD FP
Shasun FP
Source: TR Research Key: FP = Full Production, UD = Under Development
Client Confidential
30. Thank You
www.shresthpn.com
Client Confidential
